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Purpose: Patients with Parkinson's disease (PD) suffer from gait disturbance as well as lower urinary
tract symptoms (LUTS). There have been no reports that evaluated the prostate volume (PV) and
prostate-speciﬁc antigen (PSA) of patients with PD. In this study, we prospectively evaluated PV and PSA
in men with PD.
Methods: From May 2009 to January 2012, 60 PD patients and 60 age-matched non-PD patients with
LUTS enrolled at three centers in Korea. All participants (PD as well as non-PD patients) had LUTS at
presentation. We measured the PV using a transrectal ultrasonography and checked the serum PSA level
in patients with PD and their non-PD counterparts, who served as the age-matched control group, and
then compared the data of both groups. Patients with abnormal digital rectal examination results and/or
serum PSA levels >4.0 ng/mL underwent prostate biopsy.
Results: The mean patient age was 71.37 ± 7.36 years and 70.85 ± 6.31 years for PD and non-PD patients
(P ¼ 0.651), respectively. There were no signiﬁcant statistical differences between the two groups in
terms of total PV (28.56 ± 14.59 in PD vs. 29.21 ± 10.41 in non-PD, P ¼ 0.727), transition zone PV
(12.72 ± 8.76 vs. 12.73 ± 6.68, P ¼ 0.993), and total serum PSA (1.88 ± 2.80 vs. 2.01 ± 2.02, P ¼ 0.759). In
the PD group, seven patients had PSA levels >4.0 ng/mL (range, 4.12e11.18 ng/mL). Among these patients,
prostate cancer (PC) was detected in two patients. In the non-PD group, PSA levels >4.0 ng/mL were
detected in nine patients (range, 4.16e8.28 ng/mL). Among these patients, PC was detected in three
patients. The PC occurrence rate was similar in both groups.
Conclusions: Our data show that a neurologic lesion causing PD does not affect PV and PSA. As both
groups have a similar PC occurrence rate, it is clear that prostate evaluation is necessary for PD as well as
non-PD patients.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Parkinson's disease (PD) is a movement disorder associatedwith
loss of dopaminergic neurons in the substantia nigra pars compacta
(SNC) and the development of Lewy bodies.1 The most strikingDeokjin-gu, Jeonju, Jeonbuk,
ier B.V. on behalf of Prostate Inteﬁnding of bladder dysfunction in PD patients is neurogenic detru-
sor overactivity.2e4 This can be easily explained because dopami-
nergic mechanisms are thought to play a central role in normal
micturition control, and dysfunction of these may lead to detrusor
overactivity.5
A study showed that aging has a correlation with the growth of
the prostate, which is also closely linked to serum prostate-speciﬁc
antigen (PSA) levels.6,7 Although it is not clearly explicated how to
regulate the development of prostate, neural pathways as well asrnational. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Characteristics of PD patients.
Age group
(y)
Mean age
(y)
PD patients
(n)
Time since PD
(y)
51e60 56.39 ± 2.53 5 4.86 ± 2.16
61e70 67.85 ± 1.78 23 6.75 ± 3.95
71e80 74.94 ± 2.53 28 5.27 ± 3.14
>80 85.28 ± 5.21 4 6.16 ± 4.23
All 71.37 ± 7.36 60 5.86 ± 5.58
PD, Parkinson's disease.
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growth of the prostate gland.8
It has been revealed through animal experiments that the
autonomic nervous system is highly inﬂuential on the growth and
function of the prostate. According to the study of Zermann et al.,9
central neurons play an important role in the control of the prostate
gland. However, the effects of central nervous system injuries as PD
on prostatic growth and function are less well examined.
As the population is aging, the burden of neurological disorders
is increasing but access to care is limited. In particular, a consid-
erable number of patients with PD suffer from gait disturbance as
well as lower urinary tract symptoms (LUTS). There are no reports
that have evaluated the prostate activity of patients with PD.
Therefore, we prospectively evaluated the prostate volume (PV)
and PSA level in men with PD.
2. Methods
2.1. Patients
From May 2009 to January 2012, 60 PD patients and 60 age-
matched non-PD patients were enrolled at three centers in Korea
(Chonbuk National University, Jeonju, South Korea; Wonkwang
University Hospital, Iksan, South Korea; and Presbyterian Medical
Center, Jeonju, South Korea). All of the enrolled patients visited the
urology department of these institutions to undergo prostate
evaluation for the relevant LUTS. Patients were excluded from the
analysis if they had a history of, or had undergone treatment for,
acute or chronic prostatitis in the past 3 months; had received a
diagnosis of prostate cancer (PC); had undergone prostate surgery
or radiation treatment; had received 5a-reductase inhibitors; or
had signs or symptoms compatible with a current urinary infection.
2.2. Methods
All patients underwent a general and urological standard eval-
uation, including a digital rectal examination (DRE), transrectal
ultrasound (TRUS) evaluation of prostate size, and a test of PSA
level. In PD patients, age, cause of PD, and duration were recorded.
Blood samples were obtained before the patients were examined
by a physician.
In this procedure, an experienced urologist performed TRUS and
DRE. A 7.0-MHz transducer (TRUS; B&K Medical, Herlev, Denmark)
was used for scanning. Total PV and transition zone (TZ) PV were
measured. Patients with abnormal DRE results and/or serum PSA
levels >4.0 ng/mL underwent prostate biopsy.
2.3. Statistical analysis
Comparisons of data for serum PSA levels and PV parameters
were made using the t test. Serum PSA levels and PV parameters
were correlated with age and duration of PD using the Spearman
correlation coefﬁcient. The statistical software package SPSS 15.0
(SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. A P
value <0.05 was considered signiﬁcant.
3. Results
A total of 120 patients were enrolled. Table 1 illustrates the
characteristics of the PD patients. The mean time between PD and
examination was 5.86 years (Table 1). The mean serum PSA level
and total PV increased with age in PD patients as well as in the
control group (Table 2). The mean age of patients was 71.37 ± 7.36
years for the PD group and 70.85 ± 6.31 years in for the non-PD
group (P ¼ 0.651). There were no signiﬁcant statistical differencesbetween two groups in terms of total PV (28.56 ± 14.59 in PD pa-
tients vs. 29.21 ± 10.41 in non-PD patients, P ¼ 0.727), TZ PV
(12.72 ± 8.76 vs. 12.73 ± 6.68, P ¼ 0.993), and total serum PSA
(1.88 ± 2.80 vs. 2.01 ± 2.02, P ¼ 0.759; Table 3). Age at the time of
the study enrollment was correlated with serum PSA level and PV
parameters in both groups, but disease duration in the PD group did
not correlate with serum PSA level and PV parameters (Table 4). In
the PD group, PSA levels >4.0 ng/mL was detected in seven patients
(range, 4.12e11.18 ng/mL). Among these patients, PC was detected
in two patients by prostate biopsy, with PSA levels of 5.51 ng/mL
and 11.18 ng/mL. In the non-PD group, PSA levels >4.0 ng/mL were
detected in nine patients (range, 4.16e8.28 ng/mL). Among these
patients, PC was detected in three patients by prostate biopsy, with
PSA levels of 4.16 ng/mL, 6.01 ng/mL, and 8.28 ng/mL. The PC
occurrence rate was similar in both groups.4. Discussion
There is increasing recognition that the nonmotor symptoms of
PD are the most troublesome as the disease advances, and promi-
nent among these are LUTS.10,11 http://www.sciencedirect.com/
science/article/pii/S0022534709000718 LUTS have a great impact
on quality of life, early institutionalization, and health economics.
http://www.sciencedirect.com/science/article/pii/
S0022534709000718 In patients with PD, the most prevalent LUTS
is nocturia and the most common urodynamic ﬁnding is detrusor
overactivity, usually with complete bladder emptying. In PD,
widespread degeneration of dopaminergic and nondopaminergic
areas involved in lower urinary tract function is prominent,
including locus coeruleus, cerebellar Purkinje cells, dorsal motor
nucleus of the vagus, intermediolateral cell column (preganglionic
neurons innervating the internal sphincter and the bladder), and
Onuf's nucleus (neurons innervating the external sphincter).12
http://www.sciencedirect.com/science/article/pii/
S0022534709000718 In PD, neurodegeneration in the nigrostriatal
dopamine system removes the tonic inhibitory control over the
pontine micturition center, resulting in decreased bladder capacity
and detrusor overactivity. http://www.sciencedirect.com/science/
article/pii/S0022534709000718 Neurogenic detrusor overactivity
in PD is easily explained, because dopaminergic mechanisms are
thought to play a central role in normal micturition control and
dysfunction of these may lead to detrusor overactivity. Dopami-
nergic neurons have both inhibitory and stimulatory effects on
micturition acting via D1 and D2 receptors, respectively. Such
neurons are of particular abundance in the SNC and the ventral
tegmental area of the midbrain.13 The most widely accepted theory
is that the basal ganglia inhibit the micturition reﬂex in the
“normal” situation via D1 receptors, and that cell depletion in the
SNC in PD results in the loss of this D1-mediated inhibition and,
consequently, detrusor overactivity. http://www.sciencedirect.
com/science/article/pii/S0022534709000718 Although impaired
relaxation or bradykinesia of the urethral sphincter has been sug-
gested to result in voiding dysfunction, http://www.sciencedirect.
Table 2
Serum PSA values and total PV of PD patients and age-matched control group.
Age group (y) PD patients (n) Serum PSA (ng/mL) Total PV
(mL)
Control group (n) Serum PSA (ng/mL) Total PV
(mL)
51e60 5 0.48 ± 0.70 23.32 ± 9.13 3 0.51 ± 0.67 21.41 ± 11.23
61e70 23 1.35 ± 1.22 25.35 ± 7.25 26 1.54 ± 0.96 23.48 ± 7.55
71e80 28 2.45 ± 1.98 31.27 ± 10.31 27 2.53 ± 1.05 34.40 ± 11.24
>80 4 2.48 ± 2.26 34.56 ± 12.23 4 2.65 ± 1.17 37.21 ± 11.45
PD, Parkinson's disease; PSA, prostate-speciﬁc antigen; PV, prostate volume.
Table 3
Comparison of PV and PSA in PD patients and control group.
PD patients Control group P
No. 60 60
Age (y) 71.37 ± 7.36 70.85 ± 6.31 0.651
Total PV (mL) 28.56 ± 14.59 29.21 ± 10.41 0.727
TZ PV (mL) 12.72 ± 8.76 12.73 ± 6.68 0.993
Serum PSA (ng/mL) 1.88 ± 2.80 2.01 ± 2.02 0.759
PD, Parkinson's disease; PV, prostate volume; PSA, prostate-speciﬁc antigen; TZ,
transition zone.
Table 4
Correlation of age, duration of PD and PV, PSA in PD patients.a)
Age (y) Duration of PD (mo)
Total PV (mL) 0.031 0.057
TZ PV (mL) 0.165 0.153
Serum PSA (ng/mL) 0.028 0.039
PD, Parkinson's disease; PSA, prostate-speciﬁc antigen; PV, prostate volume; TZ,
transition zone.
a) All correlation coefﬁcients were not statistically signiﬁcant.
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have shown that bladder outlet obstruction is not common in PD.14
http://www.sciencedirect.com/science/article/pii/
S0022534709000718.
Nevertheless, voiding symptoms in male patients with PD may
be caused by coincident benign prostate enlargement. In our study,
there are no differences in the PV parameters and serum PSA level
in PD patients comparedwith those of non-PD patients (the control
group). Considering the correlation between the function of pros-
tate and autonomic nerves, it can be assumed that patients with
spinal cord injury, whose innervation of the prostate has been
impaired, may have a difference in the size of prostate and the level
of PSA compared to healthymen.8,15,16 However, our data show that
a neurologic lesion causing PD does not affect PV and PSA as spinal
cord injury. PC was detected in two patients in the PD group and in
three patients in the non-PD group. The PC occurrence rate was
similar in both groups. Base on our data, neurologic lesion causing
PD does not affect PC occurrence.In our study, patients with PD have the usual PV and PSA as non-
PD patients. Moreover, the PC occurrence rate was similar in both
groups. In conclusion, prostate evaluation is necessary in menwith
PD as well as in non-PD patients.Conﬂicts of interest
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